This week: student debt forgiven, a union at the NIH and more
In depth: Pharmaceutical companies have condemned plans to allow federal agencies to effectively void patent rights if drugs are deemed too costly.
Full story: Drug firms criticise ‘dangerous’ policy to veto patent rights
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.